Introduction 1
Infection by retroviruses, most notably human immunodeficiency virus (HIV), causes 2 severe immunodeficiency, cancer, and anemia in humans and in many economically important 3 vertebrates. With the exception of HIV/AIDS, relatively few studies have focused on human 4 diseases arising from retroviral infections. 5
The total number of people living with HIV has continued to increase and it is estimated to 6 be about 33 million people in the world (36). There were more than 2 million new infections, and 7 about 2 million people died of acquired immunodeficiency syndrome (AIDS) related illnesses in 8
2007 (36) . Antiretroviral therapies have proved to be effective since the introduction of the 9 combination of drugs including inhibitors of the retroviral protease (PR). The PR of HIV is an 10 excellent target for chemotherapy (for reviews, see references (16, 33) ), since the PR activity is 11 essential for the maturation and infectivity of the virus (as reviewed in references (14, 21) ). 12 Specificity studies of wild type and mutant HIV PRs have provided a basis for the rational design 13 of potent, selective inhibitors (4, 30, 38) and also may help to circumvent the problems caused by 14 the rapidly developing resistance against the compounds used in therapy (28) . 15
Human T-lymphotropic virus (HTLV) infection is also a global epidemic: 10-20 million 16 individuals are estimated to be carriers of the virus, and the risk of developing disease is 17 estimated to be 5% in infected patients (15). HTLV-1 has been etiologically associated with a 18 number of diseases including adult T-cell leukemia and HTLV-1 associated myelopathy (10). 19
Studies indicate that viral replication is critical for the development of HTLV-1 associated 20 myelopathy, and initial studies suggested that blocking replication with AZT had a therapeutic 21 effect (26). HTLV PR inhibitors may also have therapeutic value in the HTLV-associated 22 diseases, similar to the successful application of HIV PR inhibitors to treat AIDS. 23 7 1
Molecular modeling 2
The sequence alignment of the proteases used in this study and the construction of molecular 3 models were described previously (1). A model of VSQNY↓PIVQ oligopeptide was docked into the 4 substrate binding site of each retroviral protease and the minimization and analysis procedure were 5 applied as described (1) with the Sybyl program package (Tripos Inc., St. Loius, MO, USA) run on 6 the Silicon Graphics Fuel computer graphics system. Sequence identity and similarity percentage 7 values for the full protease sequences as well as for the set of residues involved in the substrate 8 binding (18-20 residues of the proteases) are provided in the Supplemental Table 1 . Cavities were 9 calculated from the minimized structures containing Gly at P1, P3 or P4 position using the SiteID 10 modul of Sybyl. It should be noted that the calculated cavity volumes are comparable only for a 11 given subsite and not suitable for comparison of different subsites, as a consequence of the 12 cavity-finding algorithm of SiteID program and the diverse solvent accessibility of the binding 13 sites (e.g. S1 is fully buried while S4 is opened to the surface). The volume of the amino acid 14 residues was retrieved from the literature (41). 15
16
Results 17 complete set of relative activity values is provided in the Table 2 of the Supplemental material.  20 None of the substrates were cleavable by HTLV-1 and HFV proteases. For the other enzymes, the 21 activities were calculated relative to those obtained with the original, P1 Tyr-containing substrate. 22
The S1 binding site of the PRs appears to be hydrophobic. The HIV-1, HIV-2, EIAV, AMV, 23 1 Tyr > Leu ≅ Met > Ala, although the individual values for relative activity showed some 2 variation. MPMV and MMTV PRs were more selective for the large aromatic residues. On the 3 other hand, the PR of BLV showed the highest preference for Leu at P1, followed by Phe or Met. 4 Therefore, the S1 site is large, hydrophobic and well conserved among retroviral proteases. These 5 results agree with predictions from the molecular models that a bulky hydrophobic P1 side chain 6 will fill the S1 subsite to obtain efficient cleavage. However, there are some fine specificity 7 distinctions, in terms of whether the enzymes would also favor (or tolerate) smaller residues at 8 this position. HIV-1, HIV-2, EIAV, AMV, MMLV and WDSV proteases tolerated the smaller 9
Leu and Met residues substantially better than did MPMV and MMTV proteases (Fig. 2 , Table 2  10 of Supplemental material). Interestingly, in the case of HIV-1 PR a similar preference order of 11 Phe >> Met ≅ Tyr ≅ Leu was observed using another substrate set (Lys-Thr-Lys-Val-Xaa↓Val-12
Val-Gln-Pro-Lys) based on the HTLV-1 CA/NC (typical type-2) cleavage site (35), while HTLV-1 13 and BLV proteases preferred Phe > Leu > Tyr > Ala and Tyr ≅ Phe > Leu ≅ Met, respectively (27). 14 The strong sequence context dependence of the preference at a given site was recognized earlier 15 (reviewed in (33)). 16 17 Unlike the S1 subsite, various residues were preferred when the S3 binding sites were 19 mapped for different retroviral PRs (Fig. 3) . The complete set of relative activity values is 20 provided in the Table 3 of the Supplemental material. The HIV and EIAV PRs preferred the 21 original polar Gln at P3 (Fig. 3) , but the second best residue was a hydrophobic one (Val for HIV-22 pronounced preference for the large hydrophobic residues, Phe and Leu, characterized AMV, 1 MPMV and MMTV proteases. In fact, MMTV PR did not hydrolyze the substrates with Gly or 2 Ala at P3. Also, MPMV PR was unusual in recognizing Asp at P3 in this substrate. On the other 3 hand, the small Ala, as well as the polar Lys were preferred by the BLV PR, and Gly by the 4 WDSV PR (Fig. 3) . The size of the residue appears to be the main specificity determinant at this 5 position, since, with the exception of the WDSV PR, the size of the average volume of the two 6 most preferred P3 residues correlated well with the mean cavity of the S3 subsite of the enzymes 7 (Fig. 4) , as previously established for the P2 position (1). In the exceptional case of WDSV 8 protease, the S3 subsite binding pocket that was predicted to be relatively large and less suitable 9
for small residues at P3. However, the uncertainty of the model of WDSV protease may 10 contribute to this discrepancy. 11
12
Substrate specificity of the S4 subsite of retroviral proteases 13
Various residues were found to fit preferably to the S4 sites of the PRs, similar to the results 14 for S3, as indicated by Fig. 5 . The activities were calculated relative to that of the P4 Val-15 containing substrate instead of the original Ser-containing one, since the former was also a 16 substrate of the HTLV-1 PR. The complete data are provided in the Table 4 of the Supplemental  17 material. In the case of primate lentiviral proteases, like HIV-1 and HIV-2 proteases, the polar Ser 18 as well as the smaller Gly or Ala residues are strongly preferred. EIAV PR prefers hydrophobic 19 residues Val, Leu, Phe and Pro. AMV, MPMV and MMTV proteases preferred medium-sized or 20 large hydrophobic residues Ile, Leu and Phe (Fig. 5 ). In contrast, the BLV and WDSV proteases 21 preferred small hydrophobic residues (Ala, Pro) at P4, while MMLV protease preferred medium-22 sized polar (Ser, Thr, Asp) residues (Fig. 5) . However, this subsite lies at the PR surface, and 23 lacks the well-defined pocket of the internal subsites. For many of these PRs a correlation was 1 observed between the size of the average volume of the best two residues and the mean cavity of 2 the S4 subsite of the enzymes, similar to the results for S3. However, HIV-1 and MMLV PRs did 3 not fit this correlation for S4 (Fig. 6) , that could be due to the less well defined S4 subsites of 4 these proteases suggested by the molecular models. 5 6 Discussion 7
These results, together with the previously published analysis of the S2 subsite, provide a 8 basis for characterization of the specificity of the amino-terminal subsites (S4-S1) of retroviral 9 proteases using a type-1 cleavage site substrate, having Tyr and Pro at the site of cleavage. A 10 schematic representation of the specificities is provided in Fig. 7 . The alpharetroviral AMV and 11 betaretroviral MMTV proteases appear to share very similar specificity. All their substrate 12 binding sites are hydrophobic and large, except for the small S2 pocket (Fig. 7) . The 13 deltaretroviral BLV PR has large hydrophobic S1 and S2 pockets, and smaller S3 and S4 subsites, 14 and only the S3 subsite has some polar character. The gammaretroviral MMLV PR has a similar 15 specificity, except the S4 site appears to be small and hydrophilic. On the other hand, the 16 epsilonretroviral WDSW PR has hydrophobic S4, S1, and somewhat hydrophilic S2 and S3 17 subsites. Interestingly, the specificity of lentiviral proteases can be subdivided into two groups. 18
The primate lentiviral HIV-1 and HIV-2 PRs have a substantially different specificity as 19 compared to that of the EIAV PR, both in the hydrophobicity of the S2 and S4 subsites as well as 20 the size of S4. The important conclusion is that the specificity pattern of the subsites agrees with 21 the evolutionary relationship among the proteases as represented by the phylogenetic tree (Fig 7) . 22
For example, EIAV, AMV and MMTV share very similar specificity at S1, S2 (1) and S4 23 subsites. It is of interest to note that while the degree of sequence identity and similarity of 1 retroviral protease sequences is fairly low, the residues forming the substrate binding sites are 2 substantially more conserved (Supplemental Material, Table 1 ), a likely consequence of the 3 selective evolutionary pressure to maintain these residues as compared to those that are not 4 critical for the structure and activity of the enzyme. 5
HIV-1 PR clinical inhibitors typically only weakly inhibit, if at all, the other retroviral 6 proteases, with the exception of MMLV PR, which was inhibited by an HIV-1 PR inhibitor (5). 7
So there is an apparent contradiction between the relatively conserved substrate specificity among 8 retroviral PRs and an almost complete lack of inhibition by HIV-1 PR inhibitors. This 9 contradiction might be due to the fact that the clinical inhibitors are typically rigid molecules, 10 while substrates are more flexible, and capable of adapting to altered substrate binding sites in 11 different retroviral PRs. The same phenomenon is observed in drug resistant HIV-1 PR variants 12 (22, 29) . The development of resistance towards the drugs designed against HIV-1 PR is one of the 13 main problems in the protease inhibitor therapy of AIDS. Many of the mutations occurring in drug 14 resistance introduce amino acids that can be found at the equivalent position in other retroviral 15 proteases. Therefore, characterization of the specificity similarities and differences of these enzymes 16 may help to design broad-spectrum inhibitors against HIV-1 PR. 17
We volume of the two P3 residues for which the measured relative activity was the highest. 10 Val-Gln peptides for retroviral proteases. 12 Figure 6 . Mean cavity volume of S4 subsite of various retroviral proteases versus averaged volume 13 of the two P4 residues for which the measured relative activity was the highest. 14 Figure 7 . Phylogenetic tree and schematic representation of the preferred residues of the S4-S1 15 subsites of representative retroviral proteases. The phylogenetic tree contains Rous sarcoma virus 16 (RSV) PR while measurements were performed using AMV PR. These two PRs differ only in two 17 residues that do not influence the specificity. The size of the oval objects representing the substrate 18 amino acid side chains approximates the size of the most preferred residues. Gray objects represent 19 sites that prefer predominantly hydrophobic residues, while white objects represent sites that do not 20 discriminate based on hydrophobicity. Dashed lines for the S4 subsites indicate that these pockets 21 are less defined than the other ones, due to the proximity to the protein surface. 
